Cercare il medicinale per il nome

Monopril e Soppressione del midollo osseo

Risultato del controllo d'interazione tra il farmaco Monopril e la malattia Soppressione del midollo osseo su sicurezza in caso d'uso simultaneo.

Risultato di controllo:

Monopril <> Soppressione del midollo osseo

Rilevanza: 23.07.2019 Recensore: P.M. Shkutko, dott., in

Durante il controllo d'interazione, secondo le fonti autorevoli Drugs.com, Rxlist.com, Webmd.com, Medscape.com sono trovate le controindicazioni o gli effetti collaterali che possono danneggiare oppure intensificare l’effetto negativo in caso d'uso del farmaco in presenza di questa malattia concomitante.

Consumatore:

Gli ACE-inibitori può causare soppressione del midollo osseo, raramente in semplici individui, ma più frequentemente in pazienti con compromissione renale, specialmente se hanno anche un collageno-vascolari malattie come il lupus eritematoso sistemico o sclerodermia. Neutropenia, agranulocitosi, anemia aplastica, anemia emolitica, trombocitopenia, eosinofilia e sono stati segnalati, soprattutto con captopril. La terapia con ACE-inibitori devono essere somministrati con cautela in pazienti con preesistente discrasie ematiche o complicazioni che possono aumentare il rischio di depressione del midollo osseo durante la terapia con ACE-inibitore. Il monitoraggio della conta ematica, in particolare i globuli bianchi, dovrebbe essere considerato.

Fonte

Davies RO, Irvin JD, Kramsch PK, Walker JF, Moncloa F "Enalapril worldwide experience." Am J Med 77 (1984): 23-35
Knapp LE, Frank GJ, McLain R, Rieger MM, Posvar E, Singer R "The safety and tolerability of quinapril." J Cardiovasc Pharmacol 15 (1990): s47-55
"Product Information. Altace (ramipril)." Hoechst Marion-Roussel Inc, Kansas City, MO.
Shindo K, Matsuya F, Ura T, et al "Captopril-associated granulocytopenia in hypertension after renal transplantation." Clin Nephrol 22 (1984): 314-6
"Product Information. Capoten (captopril)." Bristol-Myers Squibb, Princeton, NJ.
Grosbois B, Milton D, Beneton C, Jacomy D "Thrombocytopenia induced by angiotensin converting enzyme inhibitors." Br Med J 298 (1989): 189-90
Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation ." Lancet 1 (1980): 927-8
Loftus WK, Ierino F, Mathew TH "Enalapril and anaemia ." Med J Aust 148 (1988): 209-10
Strair RK, Mitch WE, Faller DV, Skorecki KL "Reversible captopril-associated bone marrow aplasia ." Can Med Assoc J 132 (1985): 320-2
Forslund T, Borgmastars H, Fyrquist F "Captopril-associated leucopenia confirmed by rechallenge in patient with renal failure ." Lancet 1 (1981): 166
Torello J, Duran JA, Abadin JA "Captopril-associated aplastic anemia ." Drug Intell Clin Pharm 24 (1990): 543-4
Beroniade V "Severe side-effects of captopril in advanced chronic kidney insufficiency." Proc Eur Dial Transplant Assoc 20 (1983): 530-7
Hirakata H, Onoyama K, Iseki K, et al "Worsening of anemia induced by long-term use of captopril in hemodialysis patients." Am J Nephrol 4 (1984): 355-60
Suarez M, Ho PW, Johnson ES, Perez G "Angioneurotic edema, agranulocytosis, and fatal septicemia following captopril therapy." Am J Med 81 (1986): 336-8
Waeber B, Gavras I, Brunner HR, Gavras H "Safety and efficacy of chronic therapy with captopril in hypertensive patients: an update." J Clin Pharmacol 21 (1981): 508-16
"Product Information. Vasotec (enalapril)." Merck & Co, Inc, West Point, PA.
Alderman CP "Adverse effects of the angiotensin-converting enzyme inhibitors." Ann Pharmacother 30 (1996): 55-61
"Product Information. Univasc (moexipril)." Schwarz Pharma, Mequon, WI.
"Product Information. Aceon (perindopril)." Solvay Pharmaceuticals Inc, Marietta, GA.
Harrison BD, Laidlaw ST, Reilly JT "Fatal aplastic anaemia associated with lisinopril." Lancet 346 (1995): 247-8
Materson BJ "Adverse effects of angiotensin-converting enzyme inhibitors in antihypertensive therapy with focus on quinapril." Am J Cardiol 69 (1992): c46-53
Onoyama K, Sanai T, Motomura K, Fujishima M "Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients." J Cardiovasc Pharmacol 13 (1989): s27-30
Vidt DG, Bravo EL, Fouad FM "Captopril." N Engl J Med 306 (1982): 214-9
Pillans PI, Koopowitz A "Captopril-associated agranulocytosis: a report of 3 cases." S Afr Med J 79 (1991): 399-400
"Product Information. Accupril (quinapril)." Parke-Davis, Morris Plains, NJ.
Elis A, Lishner M, Lang R, Ravid M "Agranulocytosis associated with enalapril." Drug Intell Clin Pharm 25 (1991): 461-2
Kim CR, Maley MB, Mohler ER "Captopril and aplastic anemia." Ann Intern Med 111 (1989): 187-8
el-Makri A, Larabi MS, Kechrid C, et al "Fatal bone-marrow suppression associated with captopril." Br Med J 283 (1981): 277-8
"Product Information. Prinivil (lisinopril)." Merck & Co, Inc, West Point, PA.
Elijovisch F, Krakoff LR "Captopril associated granulocytopenia in hypertension after renal transplantation." Lancet 1 (1980): 927-8
"Product Information. Lotensin (benazepril)." Ciba Pharmaceuticals, Summit, NJ.
Edwards IR, Coulter DM, Beasley DM, MacIntosh D "Captopril: 4 years of post marketing surveillance of all patients in New Zealand." Br J Clin Pharmacol 23 (1987): 529-36
Gavras I, Graff LG, Rose BD, et al "Fatal pancytopenia associated with the use of captopril." Ann Intern Med 94 (1981): 58-9
"Product Information. Mavik (trandolapril)." Knoll Pharmaceutical Company, Whippany, NJ.
Chalmers D, Whitehead A, Lawson DH "Postmarketing surveillance of captopril for hypertension." Br J Clin Pharmacol 34 (1992): 215-23
Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE "Enalapril-associated anemia in renal transplant recipients treated for hypertension." Am J Kidney Dis 17 (1991): 199-205
"Product Information. Monopril (fosinopril)." Bristol-Myers Squibb, Princeton, NJ.
Israeli A, Or R, Leitersdorf E "Captopril-associated transient aplastic anemia." Acta Haematol 73 (1985): 106-7